Vasoactive intestinal peptide differentially modulates human immunoglobulin production (Q41099060)

26 September 2017

1 reference

title

Vasoactive intestinal peptide differentially modulates human immunoglobulin production (English)

1 reference

26 September 2017

Kimata H

1

1 reference

26 September 2017

publication date

1 January 1996

1 reference

Advances in neuroimmunology

26 September 2017

published in

1 reference

26 September 2017

volume

6

1 reference

26 September 2017

issue

1

1 reference

26 September 2017

page(s)

107-115

1 reference

Effects of high in vivo levels of vasoactive intestinal polypeptide on function of circulating lymphocytes in humans

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Vasoactive intestinal polypeptide is synthesized in anterior pituitary tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Effects of neuropeptides on neutrophil migration through noncellular and endothelial barriers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Vaso-active intestinal peptide: a neurotransmitter which reduces human NK cell activity and increases Ig synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Vasoactive intestinal peptide stimulates immunoglobulin production and growth of human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Vasoactive intestinal peptide specifically induces human IgA1 and IgA2 production

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Nerve growth factor specifically induces human IgG4 production

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Integrated communication between the nervous, endocrine and immune systems

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Shifts in interleukin-4 and interferon-γ production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Production of interleukin-6 by anterior pituitary cells is stimulated by increased intracellular adenosine 3',5'-monophosphate and vasoactive intestinal peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Multiple sclerosis: The blood-brain-barrier and the measurement of de novo central nervous system IgG synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Oligoclonal IgG Antibody Response in the Central Nervous System to Different Measles Virus Antigens in Subacute Sclerosing Panencephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

Modulation of human IgE synthesis by transforming growth factor-β

1 reference

https://api.crossref.org/works/10.1016%2FS0960-5428%2896%2900004-6

7 January 2021

10.1016/S0960-5428(96)00004-6

Identifiers

DOI

1 reference

26 September 2017

1 reference